MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
Year: 2026
Type: conference-abstract
Authors: Ashutosh Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, Efstathios Kastritis, Divaya Bhutani, Giada Bianchi, Victor Jimenez Zepeda, Kenshi Suzuki, Suzanne Lentzsch, Antoine Huart, Alexander Carpinteiro, E Scott Swenson, Zilehuma Khan, Julia Catini, Hrishikesh Kulkarni, Brian Meltzer, Michele Mercuri, Stephen Lake, Michaela Liedtke
Institutions: University College London, Mayo Clinic, Boston University, Boston Medical Center, National and Kapodistrian University of Athens, Columbia University Irving Medical Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, University of Calgary, Japanese Red Cross Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University, Centre Hospitalier Universitaire de Toulouse, Essen University Hospital, Stiftung Universitätsmedizin Essen, University of Duisburg-Essen, AstraZeneca (United States), Alexion Pharmaceuticals (United States), Stanford Medicine, Stanford University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7204707732
Cites:
Cited by:
Related to: